Highlights from the 10th European AIDS Conference (EACS): A CME Newsletter

Library of Posters from the 10th EACS


Aplaviroc (APL, 873140), an Entry Inhibitor that Targets CCR5, Exhibits Potent In Vitro Inhibition of HIV-1 from Different Subtypes and from Individuals Failing Standard Antiretroviral Therapy (ART)
C LaBranche1 and others.


Number Population And Clonal Sequence Analyses Before And After Selection of Reverse Transcriptase Mutation L74V In HIV-1 Positive Subjects Treated With Abacavir (ABC)/Lamivudine (3TC)/Efavirenz (EFV)
A Moffattand others.


APVF 3032 Study: Efficacy and Pharmacologic Evaluation at Week 4 of Fosamprenavir/R (Fapv/R) BID in HIV, Pretreated Patients Switching from Amprenavir/R (AGN/R) with Controlled Plasma Viremia
J Reynes and others.


Combivir vs. Generic Zidovudine and Epivir:An Economic Modeling Study
K Simpson and others.


The Pharmacokinetic Interaction Between Fosamprenavir/Ritonavir and Atazanavir in Healthy Adult Subjects (APV10018)
M Wire and others.


Predictive Value of Phenotypic Inhibitory Quotient (PIQ) for Clinical Response to Fosamprenavir/ritonavir Combination Therapy
F Xu and others.


Number Genotypic and Phenotypic Analysis of Brecanavir (GW640385): An Assessment of the Effects of Specified Resistance-associated Mutations Alone or in Combination With Others in a Survey of 50 Viruses from Protease Inhibitor (PI)-Experienced Patients
P Yates and others.


L957 Improved Metabolic Profile with Replacement of Stavudine by Tenofovir DF After 6 Years of a LPV/r-Based Regimen
B da Silva and others.


Differences in Adverse Event Profiles in Antiretroviral-Naive Subjects Starting Antiretroviral Therapy with CD4 Counts <50 Cells/mm3 vs. >200 Cells/mm3: Does Immune Reconstitution Inflammatory Syndrome (IRIS) Play a Role?
C Fichtenbaum and others.